Diabetic Cardiomyopathy - Pipeline Insight, 2024

This “Diabetic Cardiomyopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Cardiomyopathy Understanding

Diabetic Cardiomyopathy: Overview

Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.

Diabetic Cardiomyopathy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.

Diabetic Cardiomyopathy Emerging Drugs Chapters

This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Cardiomyopathy Emerging Drugs

IMB-1018972: Imbria PharmaceuticalsMechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiaomyopathy
AT-001: Applied TherapeuticsAT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.

Diabetic Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Cardiomyopathy

There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.

Diabetic Cardiomyopathy Report Insights

• Diabetic Cardiomyopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Cardiomyopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Cardiomyopathy drugs?
• How many Diabetic Cardiomyopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Cardiomyopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Imbria Pharmaceuticals
• Applied Therapeutics

Key Products

• IMB-1018972
• AT-001

This product will be delivered within 2 business days.